ong Chain Omega-3 Polyunsaturated Fatty Acids and Heart Health in Humans

Not Applicable

Recruiting

• Conditions: Mild hypertriglyceridaemic subjects; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12607000566437
• Lead Sponsor: niversity of Wollongong

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-11-05
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 120

Inclusion Criteria

Female, generally healthy, regular menstrual cycles, plasma triglycerides >1.0mmol/L at screening visit.

Exclusion Criteria

Pregnant, irregular menstrual cycles, anemia, or plasma triglycerides < 1mmol/L at screening visit.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting plasma triglycerides (measured using an autoanalyser (Konelab, Thermo Electron) and standard assay kits.[At baseline and approximately 8 weeks after start of intervention (2 menstrual cycles)]

Secondary Outcome Measures

Name	Time	Method
ipoprotein levels and particle size (VLDL, IDL, LDL and HDL). Lipoproteins will be isolated from plasma using sequential ultracentrifugation. Particle size will be determined using gradient gel electrophoresis, and composition analysis will be conducted using an autoanalyser.[At baseline and approximately 8 weeks after start of intervention (2 menstrual cycles)];Fatty acid profile of erythrocytes, plasma and whole blood from the fingertip.[At baseline and approximately 8 weeks after start of intervention (2 menstrual cycles)];Blood pressure[At baseline and approximately 8 weeks after start of intervention (2 menstrual cycles)];Glucose and insulin levels, which will be meaured using Enzyme-Linked ImmunoSorbent Assay (ELISA)[At baseline and approximately 8 weeks after start of intervention (2 menstrual cycles)]